An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease

Brief description of study

The purpose of the study is to determine the safety and tolerability of the investigational product CYAD-211 when administered as a single infusion after a non-myeloablative preconditioning chemotherapy. We want to know the recommended dose for the CYAD-211 over the course of the study, by increasing the dose levels. The CYAD-211 drug substance is a cell suspension composed of allogeneic T-cells derived from healthy donor peripheral blood mononuclear cells. The study product CYAD-211 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s19-00434 Identifier: NCT04613557

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.